Athenex's Klisyri (tirbanibulin) Receives the US FDA's Approval for Actinic Keratosis on the Face or Scalp
Shots:
- The approval is based on P-III studies KX01-AK-003 and KX01-AK-004 that evaluated the efficacy and safety of Klisyri (tirbanibulin- ointment 1%- 10 mg/g) vs vehicle in 702 adult patients in the ratio of (1:1) with actinic keratosis of the face or scalp
- Both the studies achieved their 1EPs defined as 100% clearance of the AK lesions @57 days within the treatment areas- complete clearance (44% vs 5% and 54% vs 13%) respectively
- Klisyri is the first FDA approved product for Athenex and will be launched in partnership with Almirall in the US during Q1’21
Ref: GlobeNewswire | Image: Athenex
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com